Zomedica Corp. (ZOMDF)
OTCMKTS · Delayed Price · Currency is USD
0.1116
+0.0005 (0.45%)
Nov 28, 2025, 12:32 PM EST
Zomedica Revenue
Zomedica had revenue of $8.10M in the quarter ending September 30, 2025, with 15.69% growth. This brings the company's revenue in the last twelve months to $29.45M, up 10.20% year-over-year. In the year 2024, Zomedica had annual revenue of $27.29M with 8.33% growth.
Revenue (ttm)
29.45M
Revenue Growth
+10.20%
P/S Ratio
3.71
Revenue / Employee
193.78K
Employees
152
Market Cap
109.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.29M | 2.10M | 8.33% |
| Dec 31, 2023 | 25.19M | 6.26M | 33.05% |
| Dec 31, 2022 | 18.93M | 14.80M | 358.02% |
| Dec 31, 2021 | 4.13M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Global Cord Blood | 196.10M |
| Elite Pharmaceuticals | 122.89M |
| Mid-Atlantic Home Health Network | 27.00M |
| Silence Therapeutics | 25.83M |
| Tian'an Technology Group | 2.12M |
Zomedica News
- 6 days ago - Zomedica Corp. (ZOMDF) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - Zomedica Announces "Friday at Four" Webinar on November 21st Providing Strategic Overview & Third Quarter 2025 Business Review - Accesswire
- 22 days ago - Zomedica Achieves ISO 13485 Certification, Underscoring Strengthened Quality Infrastructure and Commercial Potential - Accesswire
- 23 days ago - Zomedica Announces Third Quarter 2025 Financial Results: Revenue up 16% to $8.1 Million with 67% Gross Margins and $54 Million in Liquidity to Support Growth - Accesswire
- 5 weeks ago - Zomedica Announces Launch of the Assisi Loop Lounge(R), Scientifically Backed tPEMF(TM) Therapy for Pets - Accesswire
- 6 weeks ago - Zomedica Expands Grovet's Distribution Agreement to Include Zomedica's Diagnostic and Therapeutic Device Products Across the European Union - Accesswire
- 7 weeks ago - Zomedica to Spotlight VETGuardian(R) Zero Touch(TM) Monitor in October "Fourth Friday at Four" Webinar - Accesswire
- 2 months ago - Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay - Accesswire